Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PIK3CA E542K |
| Therapy | RLY-2608 |
| Indication/Tumor Type | estrogen-receptor positive breast cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA E542K | estrogen-receptor positive breast cancer | predicted - sensitive | RLY-2608 | Case Reports/Case Series | Actionable | In a clinical case study, treatment with RLY-2608 resulted in a partial response with disappearance of the soft tissue target lesion, which was ongoing at day 141, in a patient with ESR1/PGR-positive, ERBB2 (HER2)-negative breast cancer harboring PIK3CA E542K (PMID: 37916956; NCT05216432). | 37916956 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (37916956) | Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia. | Full reference... |